1. Home
  2. Resources
  3. Organ on a chip & MPS

Organ-on-a-chip Partnerships

Cells for microphysiological in vitro systems

Human iPSC derived cells for microfluidic & organ-on-a-chip platform providers

Here at Axol, we use iPSCs to build more relevant models of human disease to expand your understanding and de-risk drug development. Our history and experience in this field date back to 2006 at the Roslin site in Edinburgh, famous for Dolly the sheep.

Central to the company’s capabilities is a library of human donor iPSCs, axoLines™, from which we offer out-sourcing iPSC-related project work in axoServices™, and highly consistent and quality differentiated end point axoCells™.

Axol are a major B2B supplier of cells to platform providers in the MPS, microfluidic and organ-on-a chip (OOC) space. We prioritize the consistency and quality of cell products, and the ease and speed of protocols; both are key to the overall partner and end-customer satisfaction, and we see your success closely linked to our success.

axoCells from Axol Bioscience

Highlights

  • Axol Bioscience is a leading supplier of cells used in microfluidic / MPS / OOC platforms
  • Specialist in sensory and motor neurons
  •  We partner with platform providers to supply high-quality cells for R&D and commercial resale/ through-sale
  •  With our custom axoServicesTM offering, we offer in-house R&D project capabilities for platform providers, to accelerate your product development and delivery

Cell types

Our axoCells™ product portfolio includes three focus areas where we provide cells, media, and reagents:
– Central nervous system cells – for neurodegenerative diseases and function
– Peripheral nervous system cells – for pain, sense, heat and touch
– Cardiac cells – for research and cardiotoxicity

Consistency is everything

Our Quality Management System is the bedrock for our daily work, driving quality and consistency for our customers. Bulk / same batch manufacturing and storage are available.

– Our manufacturing facilities are ISO 9001:2015 accredited
– We conduct in-depth iPSC characterisation, both pre- and post-differentiation
– Our Certificate of Analysis inserts report on the quality testing methods and results
– We provide full batch control and options of ownership
– There is full traceability of material origin and source
– We utilise a Q-Pulse Quality Management System for compliant audit-trail operation

axoCells Human iPSC-Derived Sensory Neuron Maximizer Kit

Organ on a chip

Organ-on-a-Chip, also known as Organs-on-chips (OoCs) or microphysiological systems (MPS) are going to be a major focus of interest in the advancement of ‘more human’ in vitro platforms. In principle, chips are microfluidic device containing networks of hair-fine microchannels for guiding and manipulating minute volumes (picolitres up to millilitres) of solution.

With the aim of better mimicking human physiology, and using human iPSC derived cells, the chips are designed to control cell microenvironments, facilitate  cell to cell interactions and maintain tissue-specific functions.
This narrative logically follows on from the development from single cell 2D cell cultures, co-cultures, 3D cell cultures, organoids and now organ-on-a-chip

Learn more

https://axolbio.com/publications/netri-axol-bioscience-press-release-january-10th-2023/

• Leung, C.M., de Haan, P., Ronaldson-Bouchard, K. et al. A guide to the organ-on-a-chip. Nat Rev Methods Primers 2, 33 (2022). https://doi.org/10.1038/s43586-022-00118-6

https://www.congress.gov/bill/117th-congress/house-bill/2565/text?q=%7B%22search%22%3A%5B%22H.R.+1%22%5D%7D&r=33&s=1

Case study: NETRI

Neurological microfluidic devices, powered by axoCells.

We partner non-exclusively with a range of platform suppliers. One example is with NETRI, where we publicly announced a business agreement to commercialize kits comprising NETRI’s organ-on-a-chip devices and Axol Bioscience’s hiPSC-derived cells.

Initially, this partnership aims to offer three sets of models to customers based on current applications using Axol Bioscience’s hiPSC-derived cells in NETRI’s microfluidic devices for:

– Peripheral nerve injury: using Axol Bioscience’s hiPSC-derived sensory and motor neurons with the axotomy capability of NETRI’s DuaLink Delta Ultra;
– Peripheral neuropathic pain: hiPSC-derived sensory neurons with chemically induced injuries in NETRI’s DuaLink MEA platform (Multi-Electrode Array) powered by AxionBiosystems;
– Allodynia, nociceptive pain, and sensitive skin syndrome: hiPSC and primary co-culture of sensory neurons and keratinocytes in NETRI’s DuaLink Ultra and DuaLink MEA to perform screening of reference compounds and electrophysiology readouts.

Let’s talk:

We look forward to building further relationships in this market space and welcome enquiries to operations@axolbio.com ahead of a confidential discussion.